Brought to you by 
Roche to promote Digene's HPV test
11 Jun 2001
Executive Summary
Roche Molecular Systems will co-exclusively market Digene Corp.'s (RNA and DNA diagnostics) human papilloma nucleic acid tests in Europe, the Middle East, and Africa. Digene is terminating its previous agreement that gave Abbott the rights in those territories.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche to promote Digene's HPV test
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice